

Date: February 18, 2025

BSE Limited

P J Towers,
Dalal Street,
Mumbai – 400 001

National Stock Exchange of India Limited

Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Script Code: 543904

Symbol: MANKIND

Dear Sir/ Madam,

**Subject: Intimation under Regulation 30 and 51 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”)-
Completion of term of Independent Director**

Pursuant to Regulation 30 and 51 of the Listing Regulations, this is to inform you that the second consecutive term of Mr. Surendra Lunia as an Independent Director of the Company has completed today i.e. on February 18, 2025, consequently, he ceases to be an Independent Director of the Company, effective from the close of business hours on February 18, 2025.

The Board of Directors and the Management of the Company place on record their sincere appreciation for the valuable contribution and guidance provided by Mr. Surendra Lunia during his association with the Company as an Independent Director.

The details as required under Listing Regulations read with SEBI circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 November 11, 2024, is enclosed herewith as Annexure-A.

You are requested to kindly take the above information on your records.

Thanking You,

Yours Faithfully,

For **Mankind Pharma Limited**

Hitesh Kumar Jain
Company Secretary and Compliance Officer

Encl.: A/a

Annexure-A**Details under Regulation 30 and 51 of Listing Regulations read with SEBI circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 November 11, 2024**

S. No.	Particulars	Details
1.	Reason for change	Completion of tenure of Mr. Surendra Lunia, Independent Director of the Company
2.	Date of Cessation	Effective from the close of business hours on February 18, 2025
3.	Brief profile	Not Applicable
4.	Disclosure of relationships between directors	Not Applicable

MANKIND PHARMA LIMITED